Longeveron (LGVN) – Momentum Movers
-
Longeveron (LGVN) CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at AAIC
-
Longeveron (LGVN) Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to LGVN Stock Lookup